President Trump has already pushed through new drug pricing deals, and that matters for patients feeling squeezed at the pharmacy counter. But the bigger fight is not just about what Americans pay today, it is about who has been carrying the load for decades while wealthy countries get cheap access to innovation. The real pressure point sits overseas, where governments have long kept prices low and let the U.S. shoulder the heavy cost of discovery.
For years, countries like Germany, Japan, France, Switzerland, and the United Kingdom have leaned on price controls, rebates, and delays to hold down what they pay for new medicines. That sounds nice on paper, but it comes with a hidden bill. American patients and taxpayers end up financing a huge share of the research that turns lab work into real treatments.
The imbalance is hard to miss. The United States accounts for roughly three-quarters of pharmaceutical profits and more than half of global research and development spending, even though it represents a much smaller slice of the world economy. That means Americans are not just buying medicine, they are underwriting the pipeline that keeps the next generation of therapies moving.
That is why simply squeezing drugmakers harder at home can backfire. Lower prices may look good in the short run, but if the money coming in drops too far, the incentive to fund risky, expensive research starts to wobble. A system that punishes innovation eventually leaves patients with fewer treatments and slower breakthroughs.
The sharper approach is to make foreign governments pay a fairer share. If the U.S. keeps pressing manufacturers only on the domestic side, it risks importing the same bargain-basement pricing rules that have distorted foreign markets for years. That would not solve the problem, it would just spread the damage and weaken the American biotech sector in the process.
Some lawmakers have floated most-favored-nation pricing, a model that would chain U.S. prices to the artificially low numbers seen abroad. That might sound like a clever shortcut, but it would lock in foreign price controls and drain the resources that fuel future drug development. It could also hit jobs, discourage new manufacturing investment, and leave American companies less able to compete in a tougher global race, especially against China.
Trump’s negotiating style gives the White House a different toolset. Instead of accepting the status quo, the administration can put direct pressure on trading partners and demand real concessions. The recent arrangement with Britain, which will raise its contribution toward new medicines, shows how that strategy can shift more of the burden away from American patients.
Germany is the next obvious target, and the administration has already moved by opening a formal look at how German price controls affect U.S. commerce. That kind of scrutiny matters because it creates leverage. Once foreign policymakers know the U.S. is serious, the conversation changes fast.
The same basic playbook can be used with Japan, France, and Switzerland. Japan, for example, routinely cuts prices on many newly launched medicines, which helps its own budget but leaves others carrying the tab. That is exactly the kind of free-riding that has distorted the system for too long.
The payoff from fixing it could be enormous. One analysis says that if other developed countries simply paid U.S. prices for new prescription drugs, global pharmaceutical revenue would jump by more than $254 billion. That kind of money would not just help companies, it could spark more research, more investment, more jobs, and a faster path to better treatments for patients everywhere.
Trump has already shown he is willing to take on the mess instead of pretending it is normal. The next move is to keep the pressure pointed where it belongs, on the wealthy countries that have been getting a bargain while America funds the engine. If those nations finally step up, U.S. patients could see lower prices without gutting the innovation that keeps new medicines coming.
